Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268937
Max Phase: Preclinical
Molecular Formula: C27H24ClN3O3S
Molecular Weight: 506.03
Associated Items:
ID: ALA5268937
Max Phase: Preclinical
Molecular Formula: C27H24ClN3O3S
Molecular Weight: 506.03
Associated Items:
Canonical SMILES: COc1ccc2c(c1)c(CC(=O)NC(=S)Nc1ccc(C)cc1)c(C)n2C(=O)c1ccc(Cl)cc1
Standard InChI: InChI=1S/C27H24ClN3O3S/c1-16-4-10-20(11-5-16)29-27(35)30-25(32)15-22-17(2)31(24-13-12-21(34-3)14-23(22)24)26(33)18-6-8-19(28)9-7-18/h4-14H,15H2,1-3H3,(H2,29,30,32,35)
Standard InChI Key: OQOQKNZFRFFKNQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 506.03 | Molecular Weight (Monoisotopic): 505.1227 | AlogP: 5.66 | #Rotatable Bonds: 5 |
Polar Surface Area: 72.36 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.25 | CX Basic pKa: | CX LogP: 6.02 | CX LogD: 6.02 |
Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.34 | Np Likeness Score: -1.52 |
1. Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K.. (2022) Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors., 13 (5.0): [PMID:35685617] [10.1039/d1md00280e] |
Source(1):